Company: IOBT
Filing Date: 2025-04-30
Form Type: 8-K
Source: 0001193125-25-107501
Chunk: 1

Company: IO Biotech, Inc.
Filing Date: 2025-04-30
Form: 8-K
Item: Item 8.01
Chunk 1
---
Item 8.01.      Other Events  

As previously announced, on December 19, 2024, IO Biotech ApS, a private limited liability company incorporated in Denmark and wholly-owned subsidiary (the “ Borrower”) of IO Biotech, Inc., a Delaware corporation (the “ Company”) entered into a Finance Contract (the “ Finance Contract”) and a related side letter with the European Investment Bank (“ EIB”), establishing three committed tranches and one uncommitted tranche of potential financing in an aggregate principal amount of up to €57.5 million, subject to certain conditions precedent.

Pursuant to the Finance Contract, the Company (through the Borrower) has satisfied the conditions to draw €10.0 million in an initial tranche of the term loan facility (“ Tranche A”). In connection therewith, on April 24, 2025, the Company issued to EIB a Tranche A warrant (the “ Tranche A Warrant”) to purchase up to 5,623,664.38 shares of the Company’s common stock, par value $0.001 (the “ Common Stock”). The Strike Price (as defined in the Tranche A Warrant) per share of Common Stock is $0.8891. It is expected that the Company (through the Borrower) will draw down upon the Tranche A loan on or around May 6, 2025.

Except as disclosed herein, the terms and conditions under the Tranche A Warrant are as disclosed under the heading “ Warrants” on our Form8-Kfiled with the U. S. Securities and Exchange Commission on December 20, 2024.